<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-150084" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nitisinone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Elder</surname>
            <given-names>Adam J.</given-names>
          </name>
          <aff>Wayne State University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ali</surname>
            <given-names>Sablaa</given-names>
          </name>
          <aff>West Virginia School of Osteopathic Medicine, Lewisburg, WV</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adam Elder declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sablaa Ali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-150084.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">First approved by the FDA in 2002, nitisinone is used to treat hereditary tyrosinemia type 1 (HT-1), an autosomal recessive disorder caused by a deficiency in fumarylacetoacetate hydrolase (FAH). This condition&#x000a0;involves the accumulation of toxic intermediates in the tyrosine degradation pathway, resulting in severe liver and kidney damage. Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase, effectively reducing the buildup of these harmful metabolites and preventing further organ damage. Monitoring succinylacetone levels in the blood is crucial for assessing treatment efficacy in&#x000a0;patients with HT-1.</p>
        <p>Nitisinone has also&#x000a0;demonstrated effectiveness&#x000a0;in managing alkaptonuria, a metabolic disorder characterized by the accumulation of homogentisic acid, which causes&#x000a0;ochronosis, among other things. Studies reveal that higher doses of nitisinone significantly decrease urine and serum homogentisic acid levels, though an increased risk of adverse effects exists. Clinicians prescribing nitisinone should monitor patients closely for side effects and adjust dosing accordingly.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine the mechanism of action of nitisinone.</p></list-item><list-item><p>Assess the indications for nitisinone therapy.</p></list-item><list-item><p>Identify&#x000a0;the contraindications and&#x000a0;adverse effects&#x000a0;associated with nitisinone therapy.</p></list-item><list-item><p>Determine&#x000a0;the importance of interprofessional team collaboration and communication to improve health outcomes for patients receiving treatment with nitisinone.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=150084&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=150084">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-150084.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Nitisinone, or 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC), was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of hereditary tyrosinemia type 1 (HT-1), in 2002.&#x000a0;This drug was first discovered as a triketone molecule part of herbicidal weed killers.<xref ref-type="bibr" rid="article-150084.r1">[1]</xref><xref ref-type="bibr" rid="article-150084.r2">[2]</xref></p>
        <p>HT-1 is an autosomal recessive disease&#x000a0;that results in&#x000a0;a deficiency in fumarylacetoacetate hydrolase (FAH), the&#x000a0;final enzyme in the tyrosine degradation pathway.<xref ref-type="bibr" rid="article-150084.r3">[3]</xref>&#x000a0;Among the general population, HT-1 has a prevalence of about 1 in every 100,000 newborn infants. Symptoms of HT-1&#x000a0;arise early in life, and diagnosis is made via molecular and enzyme studies. Death occurs within 24 months if treatment is not initiated as soon as possible.<xref ref-type="bibr" rid="article-150084.r4">[4]</xref></p>
        <p>HT-1 complications arise from the accumulation of tyrosine and intermediate products fumarylacetoacetate (FAA) and maleylacetoacetate (MAA). FAA deposition in renal tubules and hepatocytes precipitates end-organ damage. FAA and MAA are further broken down into toxic metabolites succinylacetoacetate (SAA) and succinylacetone (SA) in patients with HT-1.<xref ref-type="bibr" rid="article-150084.r5">[5]</xref><xref ref-type="bibr" rid="article-150084.r6">[6]</xref></p>
        <p>Subsequent elevations of SAA and SA further exacerbate liver and kidney toxicity. Rickets, cognitive impairments, jaundice, vomiting, persistent irritability, and renal tubular dysfunction are among the most common symptoms of&#x000a0;HT-1.<xref ref-type="bibr" rid="article-150084.r5">[5]</xref>&#x000a0;Hepatocellular carcinoma (HCC) is a late complication of hereditary tyrosinemia type 1 and is a significant cause of death.<xref ref-type="bibr" rid="article-150084.r7">[7]</xref>&#x000a0;Patients with HT-1 are more likely to progress to hepatocellular carcinoma (HCC), especially when they are not provided with proper neonatal screening or access to NTBC medication. Recurring checkup appointments should be scheduled to monitor for HCC.<xref ref-type="bibr" rid="article-150084.r7">[7]</xref>&#x000a0;&#x000a0;</p>
        <p>Elevated SA levels can also cause reduced heme synthesis&#x000a0;by inhibiting delta-aminolevulinic acid dehydratase (&#x003b4;-ALAD),&#x000a0;an enzyme that catalyzes the conversion of aminolevulinic acid to porphobilinogen. At this point, an interruption of the heme synthesis pathway causes an&#x000a0;accumulation of aminolevulinic acid (ALA); this same step in heme synthesis is inhibited by lead. Therefore, it would not be unusual for a patient with HT-1 to experience porphyria-type symptoms similar to lead poisoning.<xref ref-type="bibr" rid="article-150084.r8">[8]</xref><xref ref-type="bibr" rid="article-150084.r9">[9]</xref></p>
        <p>Succinylacetone is a reliable screening marker in the diagnosis and screening of HT-1. Succinylacetone is also the preferred marker when monitoring treatment efficacy.<xref ref-type="bibr" rid="article-150084.r10">[10]</xref>&#x000a0;Methionine elevation&#x000a0;is observed during hepatocellular injury in patients with&#x000a0;HT-1.<xref ref-type="bibr" rid="article-150084.r4">[4]</xref>&#x000a0;Before the utilization of NTBC, the definitive treatment for HT-1 was liver transplantation. This therapy method is still used for&#x000a0;patients with HT-1 who are refractory to NTBC treatment.<xref ref-type="bibr" rid="article-150084.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Non&#x02013;FDA-approved indications for NTBC use include the management of alkaptonuria.<xref ref-type="bibr" rid="article-150084.r12">[12]</xref>&#x000a0;Alkaptonuria is an autosomal recessive disorder in which homogentisic acid (HGA), a pigmenting toxic metabolite, accumulates in cartilage, sclera, and connective tissues (ochronosis).<xref ref-type="bibr" rid="article-150084.r13">[13]</xref>&#x000a0;</p>
        <p>Recent studies suggest that NTBC therapy may be more beneficial in treating patients with alkaptonuria than those with HT-1.&#x000a0;A recent study investigated nitisinone's effectiveness in treating alkaptonuria by comparing a 2 mg dose of nitisinone&#x000a0;to a 10 mg dose. The results&#x000a0;suggest&#x000a0;that nitisinone 10 mg slows the progressive disease course of alkaptonuria and leads to a more significant decrease in urine and serum HGA levels. The study also highlighted the increased likelihood of developing adverse effects with a higher dose of nitisinone compared to the lower amount and the benefit of concurrent adherence to a low-protein diet.<xref ref-type="bibr" rid="article-150084.r14">[14]</xref></p>
        <p>More recently, nitisinone has been explored for its potential use in improving regional hypopigmentation in patients with albinism. Multiple subtypes of oculocutaneous albinism (OCA) exist, and mutations in the tyrosinase gene cause this inherited disorder. A deficiency in tyrosinase leads to&#x000a0;reduced melanin synthesis. This lack of melanin gives patients with OCA the classical&#x000a0;hypopigmented skin, eyes, and hair follicles.<xref ref-type="bibr" rid="article-150084.r15">[15]</xref>&#x000a0;</p>
        <p>One group of researchers tested the efficacy of nitisinone therapy in treating&#x000a0;5 patients with OCA-1B. Their results concluded that nitisinone might prove beneficial in increasing the pigmentation of the skin and hair in patients with OCA-1B.<xref ref-type="bibr" rid="article-150084.r16">[16]</xref></p>
      </sec>
      <sec id="article-150084.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nitisinone&#x000a0;inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD), blocking the second step in the tyrosine degradation pathway before the deficient FAH enzyme causes HT-1.<xref ref-type="bibr" rid="article-150084.r17">[17]</xref>&#x000a0;By inhibiting tyrosine metabolism upstream of FAH, NTBC prevents the accumulation of toxic metabolites in the tyrosine degradation pathway.&#x000a0;HPPD is also upstream of homogentisate oxidase, another enzyme in the tyrosine degradation pathway deficient in alkaptonuria.<xref ref-type="bibr" rid="article-150084.r12">[12]</xref><xref ref-type="bibr" rid="article-150084.r18">[18]</xref>&#x000a0;Therefore, inhibiting HPPD with nitisinone before the deficient step catalyzed by homogentisate oxidase in alkaptonuria will prevent homogentisic acid accumulation.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;The pharmacokinetic characteristics following a single oral administration of nitisinone 30 mg&#x000a0;in fasting patients&#x000a0;achieved a Cmax of 10.5 &#x003bc;mol/L and a Tmax of 3.5 hrs. A multi-dose&#x000a0;regimen of nitisinone 80 mg once daily achieved a Cmax of 120 &#x003bc;mol/L and a Cmax of 4 hrs. Steady-state (SS) was reached within 14 days of dosing in all subjects.</p>
        <p><bold>Distribution:</bold> In vitro studies&#x000a0;have demonstrated&#x000a0;that nitisinone&#x000a0;exhibits a human plasma protein binding of &#x0003e;95% at 50 &#x003bc;m.</p>
        <p><bold>Metabolism:</bold>&#x000a0;The mean terminal plasma half-life was 54 hours in&#x000a0;healthy males&#x000a0;receiving single-dose nitisinone.&#x000a0;In vitro&#x000a0;studies demonstrated that nitisinone is relatively stable in human liver microsomes, with minor metabolism possibly mediated by the CYP3A4 enzyme.</p>
        <p><bold>Elimination:</bold>&#x000a0;The mechanism of NTBC elimination is poorly understood. Studies involving multiple oral doses of 80 mg daily in healthy subjects showed that the mean fraction of the dose excreted as unchanged nitisinone in the urine was 3.0%,&#x000a0;suggesting that renal elimination of nitisinone is of minor importance.</p>
      </sec>
      <sec id="article-150084.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Strength and Dosage Forms</bold>
</p>
        <p>Nitisinone is&#x000a0;available as&#x000a0;pills, capsules, tablets,&#x000a0;and oral suspension. While most forms are available&#x000a0;in dosage strengths of 2 mg, 5 mg, 10 mg, and 20 mg, the oral suspension of NTBC is&#x000a0;available&#x000a0;in 4 mg/mL. The oral capsule form of NTBC is&#x000a0;administered 2 hours after meals or at least an hour before a patient plans to eat. Patients with trouble swallowing tablets can be administered NTBC through oral suspension. If&#x000a0;patients are intolerant to oral suspension or pills, the pill capsules may be opened, and the contents can be mixed with water immediately before ingesting.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>NTBC dosage is dependent on body weight (kg). The recommended initial dose should be 0.5 mg/kg twice daily. Patients with persistent detectable levels of succinylacetone in the blood and urine after administration of NTBC should have their doses increased while continuously monitoring SA levels. The maximal approved oral dosage is 2 mg/kg, administered twice daily.&#x000a0;</p>
        <p>The dosage of nitisinone is titrated for each patient based on clinical and biochemical responses:</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians should regularly monitor plasma and urine succinylacetone concentrations, &#x003b1;-fetoprotein levels, and liver function markers.</p>
          </list-item>
          <list-item>
            <p>If succinylacetone is detectable in blood or urine 4 weeks after starting nitisinone, the nitisinone dosage should be increased to 0.75 mg/kg twice daily. Based on the evaluation of all biochemical parameters, nitisinone may be titrated to a maximum daily dosage of 2 mg/kg.</p>
          </list-item>
          <list-item>
            <p>If the biochemical response is adequate (ie, succinylacetone is undetectable in blood and urine), titration should only be adjusted according to body weight gain, not plasma tyrosine levels.</p>
          </list-item>
          <list-item>
            <p>When switching from twice-daily to once-daily dosing during therapy initiation, or if the patient's condition deteriorates, it may be necessary to regularly monitor all available biochemical parameters (ie, urine 5-aminolevulinate (ALA), plasma or urine succinylacetone, and erythrocyte porphobilinogen (PBG)-synthase activity).</p>
          </list-item>
          <list-item>
            <p>The patient's&#x000a0;phenylalanine and tyrosine intake should be restricted to ensure plasma tyrosine levels&#x000a0;remain below 500 &#x003bc;mol/L.&#x000a0;The dietary tyrosine intake should be assessed in patients with plasma phenylalanine and tyrosine levels above 500 &#x003bc;mol/L. The nitisinone dosage should not be altered to&#x000a0;reduce the plasma tyrosine concentration.</p>
          </list-item>
        </list>
        <p>The oral suspension is not&#x000a0;restricted to mealtimes and&#x000a0;may be administered anytime throughout the day. Due to the polyol components included, patients receiving an oral suspension of nitisinone may experience constitutional symptoms such as diarrhea, headaches, or fatigue. The primary elimination mechanism&#x000a0;of NTBC is unknown, but it has a&#x000a0;half-life of about 54 hours.<xref ref-type="bibr" rid="article-150084.r19">[19]</xref><xref ref-type="bibr" rid="article-150084.r20">[20]</xref><xref ref-type="bibr" rid="article-150084.r11">[11]</xref><xref ref-type="bibr" rid="article-150084.r21">[21]</xref>&#x000a0;NTBC inhibits the breakdown of tyrosine, causing an increase in tyrosine concentration in the blood. Thus, it must be administered with dietary restrictions on tyrosine and phenylalanine.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No dosage adjustments are provided in the manufacturer's labeling for patients with hepatic failure.&#x000a0;</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dosage adjustments are provided in the manufacturer's labeling for patients with renal failure.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Documented cases of NTBC&#x000a0;administration&#x000a0;to pregnant&#x000a0;women with HT-1&#x000a0;suggested no harm to the patient and a complete&#x000a0;absence of fetal anomalies. Follow-up studies on infants born to HT-1-diagnosed mothers treated with NTBC while pregnant will help clarify the risks of nitisinone use in pregnancy.<xref ref-type="bibr" rid="article-150084.r22">[22]</xref>&#x000a0;</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;The advantages of breastfeeding benefits should be weighed against the mother's requirements for nitisinone and any potential risks to the breastfed infant from either the drug or the mother's medical condition.</p>
      </sec>
      <sec id="article-150084.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse reactions associated with nitisinone&#x000a0;administration&#x000a0;are categorized below by system.</p>
        <p>
<bold>Metabolic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated tyrosine levels&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
        </list>
        <p>
<bold>Hematologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Granulocytopenia</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
        </list>
        <p>
<bold>Ocular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Eye pain</p>
          </list-item>
          <list-item>
            <p>Corneal opacities</p>
          </list-item>
          <list-item>
            <p>Photophobia</p>
          </list-item>
          <list-item>
            <p>Keratitis</p>
          </list-item>
          <list-item>
            <p>Cataracts</p>
          </list-item>
        </list>
        <p>
<bold>Dermatological</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Epistaxis</p>
          </list-item>
          <list-item>
            <p>Exfoliative dermatitis</p>
          </list-item>
          <list-item>
            <p>Pruritis</p>
          </list-item>
          <list-item>
            <p>Dry skin</p>
          </list-item>
          <list-item>
            <p>Maculopapular rash</p>
          </list-item>
          <list-item>
            <p>Alopecia</p>
          </list-item>
        </list>
        <p>An elevated tyrosine level is the most common adverse effect of nitisinone therapy; this is thought to be the best predictor of all other adverse effects, especially the ocular manifestations.<xref ref-type="bibr" rid="article-150084.r23">[23]</xref><xref ref-type="bibr" rid="article-150084.r24">[24]</xref><xref ref-type="bibr" rid="article-150084.r25">[25]</xref>&#x000a0;Adverse reactions such as headaches or diarrhea may also occur&#x000a0;during nitisinone therapy, especially in&#x000a0;patients&#x000a0;receiving the oral suspension.<xref ref-type="bibr" rid="article-150084.r11">[11]</xref><xref ref-type="bibr" rid="article-150084.r21">[21]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Clinicians should be cautious about administering nitisinone to patients receiving&#x000a0;medications metabolized by specific members of the CYP 450 family of enzymes. Nitisinone may cause an increase in the concentration of drugs normally metabolized by CYP2C9 and potentially even decrease drug concentrations of substrates normally metabolized by CYP2E1.&#x000a0;Patients taking substrates of CYP2C9 should have their doses modified accordingly while also taking nitisinone to avoid toxicity and exacerbation of adverse effects.&#x000a0;Examples of drugs metabolized by CYP2C9 include amitriptyline, diclofenac, fluoxetine, ibuprofen, losartan, naproxen, piroxicam, phenytoin, tolbutamide, torasemide, and warfarin.<xref ref-type="bibr" rid="article-150084.r26">[26]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Food Interactions</bold>
</p>
        <p>Patients must adhere to a diet low in tyrosine and phenylalanine to limit adverse reactions, and tyrosine levels&#x000a0;should be&#x000a0;closely monitored&#x000a0;in patients&#x000a0;receiving nitisinone.</p>
      </sec>
      <sec id="article-150084.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no known contraindications for nitisinone in patients with hereditary tyrosinemia type 1 (HT-1).<xref ref-type="bibr" rid="article-150084.r22">[22]</xref>&#x000a0;Explorational&#x000a0;studies&#x000a0;aiming to identify potential contraindications with nitisinone treatment are currently underway.&#x000a0;One non-randomized study assessed nitisinone&#x02019;s effect on cytochrome p450 (CYP) enzymes. The investigators&#x000a0;observed changes in concentrations of drugs metabolized by specific cytochrome p450 enzymes before and after nitisinone administration. The results indicated that nitisinone was a&#x000a0;weak inducer of CYP2E1 and a modest&#x000a0;inhibitor of CYP2C9.<xref ref-type="bibr" rid="article-150084.r27">[27]</xref>&#x000a0;As discussed previously, clinicians should be cautious when administering nitisinone to patients receiving these medications.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Elevated plasma tyrosine levels:</bold> Patients should maintain a concomitant reduction in dietary tyrosine and phenylalanine while undergoing treatment with nitisinone capsules. The nitisinone dosage should not be adjusted to achieve lower plasma tyrosine concentrations. Plasma tyrosine levels should be kept below 500 &#x003bc;mol/L. Insufficient dietary restriction of tyrosine and phenylalanine can result in elevated plasma tyrosine levels, which may contribute to varying degrees of intellectual disability and developmental delays.&#x000a0;For patients&#x000a0;receiving nitisinone capsules who experience sudden changes in neurological status, a clinical laboratory assessment, including plasma tyrosine levels, should be performed.</p>
        <p><bold>Hyperkeratotic plaques:</bold> Patients may develop painful hyperkeratotic plaques on the palms and soles.</p>
        <p><bold>Leukopenia and thrombocytopenia:</bold>&#x000a0;Clinicians should monitor for these conditions as part of the treatment regimen.</p>
      </sec>
      <sec id="article-150084.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving nitisinone should&#x000a0;follow a strict diet low in phenylalanine and tyrosine. Serum levels of phenylalanine and tyrosine should be monitored continuously in patients treated with nitisinone. Phenylalanine should be restricted in the diet because it is a precursor amino acid to tyrosine when it is metabolized by phenylalanine hydroxylase. A deficiency in phenylalanine hydroxylase causes phenylketonuria (PKU).<xref ref-type="bibr" rid="article-150084.r28">[28]</xref>&#x000a0;</p>
        <p>NTBC causes an elevation of tyrosine in the blood, which is thought to be the cause of&#x000a0;various adverse effects. Laboratory studies have shown that a restrictive diet of phenylalanine alone was ineffective in preventing NTBC-induced tyrosinemia. However, the same studies proved that concurrent restriction of phenylalanine and tyrosine significantly reduces the likelihood of NTBC-induced tyrosinemia. A protein-restricted diet protein also considerably reduced tyrosinemia&#x000a0;during NTBC therapy.<xref ref-type="bibr" rid="article-150084.r29">[29]</xref>&#x000a0;Rapid neurological disturbances in patients on nitisinone therapy&#x000a0;are an indication to obtain&#x000a0;tyrosine levels.</p>
        <p>A slit-lamp exam should be&#x000a0;performed before initiating therapy because of the potential ocular adverse effects&#x000a0;associated with&#x000a0;nitisinone therapy. Patients experiencing keratopathy or other ocular manifestations should&#x000a0;undergo slit-lamp examination. One study showed that corneal keratopathy could occur asymptomatically in patients receiving nitisinone.<xref ref-type="bibr" rid="article-150084.r30">[30]</xref>&#x000a0;This finding further highlights the importance of monitoring for ocular side effects&#x000a0;in patients with HT-1 and alkaptonuria undergoing&#x000a0;NTBC therapy. &#x000a0;</p>
        <p>Platelet and white blood cell counts should be monitored due to potential hematological side effects, such as thrombocytopenia and leukopenia. This is especially true of patients presenting with signs and symptoms&#x000a0;suggesting a hematological condition.&#x000a0;If plasma tyrosine levels are elevated in individuals with HT-1 receiving dietary restrictions and nitisinone, it&#x02019;s essential to evaluate their dietary intake of tyrosine and phenylalanine.</p>
      </sec>
      <sec id="article-150084.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity due to nitisinone treatment&#x000a0;is&#x000a0;primarily&#x000a0;encountered in individuals who maintain a&#x000a0;regular diet without restricting phenylalanine and tyrosine, which precipitates symptoms of hypertyrosinemia. Tyrosine toxicity can mimic the&#x000a0;various hereditary tyrosinemia subtypes, inducing potential neurological symptoms, hyperkeratotic plaques on the palms and soles, intellectual disability, and developmental delay.<xref ref-type="bibr" rid="article-150084.r6">[6]</xref></p>
      </sec>
      <sec id="article-150084.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nitisinone is reserved for patients with&#x000a0;hereditary tyrosinemia type 1, a life-threatening metabolic disease, or alkaptonuria. Nitisinone therapy is started as soon as an infant is diagnosed. Monitoring for potential adverse effects and possible contraindications is essential to ensure a higher quality of life for patients with HT-1.</p>
        <p>Due to the autosomal recessive inheritance pattern&#x000a0;of HT-1, a symptomatic diagnosis is usually made in infancy, and nitisinone therapy must be started immediately. Developing a strong patient-physician relationship is essential, as&#x000a0;patients with HT-1 require lifelong treatment. Life-long therapy requires all interprofessional healthcare team members to be aware of a patient&#x02019;s diagnosis and&#x000a0;treatment to&#x000a0;enhance health outcomes. Treatment with nitisinone and improved healthcare team outcomes significantly increase the life expectancy of patients with HT-1.<xref ref-type="bibr" rid="article-150084.r31">[31]</xref>&#x000a0;</p>
        <p>To encourage a healthy relationship among the interprofessional healthcare team, all members should collaborate and coordinate openly and have access to the same patient information. This will set the patient up to receive the most optimal care possible. Each member offers expert input from their respective disciplines, which will enhance the patient treatment strategy, improve health outcomes, and prevent adverse effects&#x000a0;associated with nitisinone therapy.</p>
      </sec>
      <sec id="article-150084.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=150084&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=150084">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/150084/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=150084">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-150084.s11">
        <title>References</title>
        <ref id="article-150084.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuht</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Maconachie</surname>
                <given-names>GDE</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging treatments for albinism.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2021</year>
            <season>Mar-Apr</season>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>362</fpage>
            <page-range>362-377</page-range>
            <pub-id pub-id-type="pmid">33129801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lock</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>From Weed Killer to Wonder Drug.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>959</volume>
            <fpage>175</fpage>
            <page-range>175-185</page-range>
            <pub-id pub-id-type="pmid">28755195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aktuglu-Zeybek</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kiykim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cansever</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Hereditary Tyrosinemia Type 1 in Turkey.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>959</volume>
            <fpage>157</fpage>
            <page-range>157-172</page-range>
            <pub-id pub-id-type="pmid">28755194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>The genetic tyrosinemias.</article-title>
            <source>Am J Med Genet C Semin Med Genet</source>
            <year>2006</year>
            <month>May</month>
            <day>15</day>
            <volume>142C</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">16602095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).</article-title>
            <source>Appl Clin Genet</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>43</fpage>
            <page-range>43-48</page-range>
            <pub-id pub-id-type="pmid">28769581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Adnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puranik</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Hypertyrosinemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">35201733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKiernan</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Nitisinone in the treatment of hereditary tyrosinaemia type 1.</article-title>
            <source>Drugs</source>
            <year>2006</year>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>743</fpage>
            <page-range>743-50</page-range>
            <pub-id pub-id-type="pmid">16706549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beru</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sahr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goldwasser</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of heme synthesis in bone marrow cells by succinylacetone: effect on globin synthesis.</article-title>
            <source>J Cell Biochem</source>
            <year>1983</year>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-105</page-range>
            <pub-id pub-id-type="pmid">6193131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silbergeld</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Hruska</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lamon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frykholm</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Neurotoxic aspects of porphyrinopathies: lead and succinylacetone.</article-title>
            <source>Environ Res</source>
            <year>1982</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>459</fpage>
            <page-range>459-71</page-range>
            <pub-id pub-id-type="pmid">7160360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chinsky</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ficicioglu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Karnebeek</surname>
                <given-names>CDM</given-names>
              </name>
              <name>
                <surname>Grompe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Waisbren</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gucsavas-Calikoglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wasserstein</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.</article-title>
            <source>Genet Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">28771246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sniderman King</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trahms</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <chapter-title>Tyrosinemia Type I</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2006</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">20301688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Basit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>MEU</given-names>
              </name>
            </person-group>
            <article-title>Adequacy of nitisinone for the management of alkaptonuria.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>80</volume>
            <fpage>104340</fpage>
            <pub-id pub-id-type="pmid">36045846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soltysova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuzin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Samarkina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zatkova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Alkaptonuria in Russia.</article-title>
            <source>Eur J Hum Genet</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-242</page-range>
            <pub-id pub-id-type="pmid">34504318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ranganath</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Milan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Khedr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Alsbou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imrich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gornall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sireau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.</article-title>
            <source>JIMD Rep</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-92</page-range>
            <pub-id pub-id-type="pmid">35028273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubasch</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Meurer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Oculocutaneous and ocular albinism].</article-title>
            <source>Hautarzt</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>11</issue>
            <fpage>867</fpage>
            <page-range>867-875</page-range>
            <pub-id pub-id-type="pmid">29018889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Menezes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jauregui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Valivullah</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Power</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeffrey</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Garced</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alur</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wiggs</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merideth</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wakamatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Introne</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.</article-title>
            <source>JCI Insight</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>4</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30674731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lock</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>The Discovery of the Mode of Action of Nitisinone.</article-title>
            <source>Metabolites</source>
            <year>2022</year>
            <month>Sep</month>
            <day>25</day>
            <volume>12</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">36295804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolffenbuttel</surname>
                <given-names>BHR</given-names>
              </name>
              <name>
                <surname>Heiner-Fokkema</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>van Spronsen</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Preventive use of nitisinone in alkaptonuria.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2021</year>
            <month>Aug</month>
            <day>03</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>343</fpage>
            <pub-id pub-id-type="pmid">34344451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlune</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thimm</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Herebian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spiekerkoetter</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Single dose NTBC-treatment of hereditary tyrosinemia type I.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>831</fpage>
            <page-range>831-6</page-range>
            <pub-id pub-id-type="pmid">22307209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kienstra</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>van Reemst</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>van Ginkel</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Dam</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burgerhof</surname>
                <given-names>JGM</given-names>
              </name>
              <name>
                <surname>de Blaauw</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Heiner-Fokkema</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>van Spronsen</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-186</page-range>
            <pub-id pub-id-type="pmid">29170874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <source>Pharmacoeconomic Review Report: Nitisinone (MDK-Nitisinone): (MendeliKABS Inc.): Indication: for the treatment of HT-1 in combination with dietary restriction of tyrosine and phenylalanine [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2018</year>
            <month>04</month>
            <pub-id pub-id-type="pmid">30457776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sprietsma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rudnick</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>e5</fpage>
            <page-range>e5-7</page-range>
            <pub-id pub-id-type="pmid">23838819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <article-title>Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.</article-title>
            <source>Prescrire Int</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>88</issue>
            <fpage>56</fpage>
            <page-range>56-8</page-range>
            <pub-id pub-id-type="pmid">17458044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitiello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Bernardo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guercio Nuzio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mandato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vajro</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pediatric liver diseases and ocular changes: What hepatologists and ophthalmologists should know and share with each other.</article-title>
            <source>Dig Liver Dis</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">31843253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lock</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Gaskin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Auton</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Provan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Prisbylla</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Mutter</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>498</fpage>
            <page-range>498-506</page-range>
            <pub-id pub-id-type="pmid">9728330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miners</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Birkett</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>525</fpage>
            <page-range>525-38</page-range>
            <pub-id pub-id-type="pmid">9663807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huledal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000d6;nnestam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dal&#x000e9;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lindqvist</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;ijers&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>313</fpage>
            <page-range>313-320</page-range>
            <pub-id pub-id-type="pmid">30443705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhawary</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>AlJahdali</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Abumansour</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Elhawary</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Gaboon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dandini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Madkhali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alosaimi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aljohani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melibary</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kensara</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>Genetic etiology and clinical challenges of phenylketonuria.</article-title>
            <source>Hum Genomics</source>
            <year>2022</year>
            <month>Jul</month>
            <day>19</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">35854334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PJM</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Milan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bou-Gharios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ranganath</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-268</page-range>
            <pub-id pub-id-type="pmid">31503358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khedr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briggs</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Milan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>RMK</given-names>
              </name>
              <name>
                <surname>Lock</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ranganath</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.</article-title>
            <source>JIMD Rep</source>
            <year>2018</year>
            <volume>40</volume>
            <fpage>31</fpage>
            <page-range>31-37</page-range>
            <pub-id pub-id-type="pmid">28942493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150084.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holme</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lindstedt</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nontransplant treatment of tyrosinemia.</article-title>
            <source>Clin Liver Dis</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>805</fpage>
            <page-range>805-14</page-range>
            <pub-id pub-id-type="pmid">11232358</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
